Lg. Axelsson et al., EXPERIMENTAL COLITIS INDUCED BY DEXTRAN SULFATE SODIUM IN MICE - BENEFICIAL-EFFECTS OF SULFASALAZINE AND OLSALAZINE, Alimentary pharmacology & therapeutics, 12(9), 1998, pp. 925-934
Background: Animal models of inflammatory bowel disease are artificial
and more or less representative of human disease. However, the dextra
n sulphate sodium (DSS) induced intestinal inflammation model has rece
ntly been shown to fulfil some pathological criteria for an adequate e
xperimental model. Aim: To determine whether this form of experimental
intestinal inflammation responds to established therapy used for huma
n inflammatory bowel disease. Methods: DSS was used to induce intestin
al inflammation in conventional Balb/c mice and athymic nu/nu CD-1 (BR
) mice, and the well-documented 5-aminosalicylic acid (5-ASA) based an
ticolitis drugs sulphasalazine (SASP) and olsalazine (OLZ) were used t
o study therapeutic effects. Parameters which have been shown to refle
ct DSS-induced intestinal inflammation (body weight, colon length, spl
een weight, diarrhoea, and rectal bleeding) were measured in the Balb/
c mice. Results: Significant amelioration was seen on these parameters
after different treatment protocols. Survival in nu/nu CD-1 mice was
studied, and after 16 days a death rate of 50% was noted in the DSS gr
oup. SASP (100 mg/kg/day) and OLZ (50 mg/kg/day) significantly prolong
ed the survival to 29 and 38 days, respectively. SASP and OLZ showed a
dose-dependent effect in the range between 10 and 100 mg/kg/day, dose
s closely corresponding to those used in humans. Conclusions: SASP and
OLZ are able to ameliorate the DSS-induced intestinal inflammation, T
he dose-response patterns suggested that the active therapeutic moiety
for the two drugs appears to be mainly the liberated 5-ASA molecule.